XEIA Venture Partners β Full Portfolio
30 tracked investments Β· listed companies and verified rows first
Vonova develops the Cerebro Platform, a minimally invasive neurovascular system that uses the body's venous system to access the brain, guided by real-time imaging to deliver diagnostic and therapeutic treatments without drilling through the skull.
Deep TechHealthtechMedical Devices
JosΓ© Morales(Dr.)
Co-investorsSmartGateVC
Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging.
AI & Machine LearningBiotechLongevity
Martin Jacko(Founder & CEO)in
Co-investorsage1
Beond operates a medically supervised ibogaine treatment facility in Mexico that uses neuroplasticity-focused therapies to treat depression, anxiety, PTSD, trauma, TBI, and substance addictions such as opioids, fentanyl, stimulants, and alcohol use disorder.
HealthtechMental HealthWellness & Fitness
Coherence develops neurotechnology systems that measure and modulate brain activity to treat cancer and other neurological diseases.
AI & Machine LearningBiotechMedical DevicesSan Francisco, US
Ben Woodington(Co-founder & CEO)inElise Jenkins(Co-founder & CTO)in
Co-investorsArtesianBlackbird VenturesPossible VenturesSmartGateVCDivergent CapitalSciFounders+1 more
The page references health, wellbeing and performance under the banner "Human 3," alongside expertise in AI/ML, medicinal chemistry/pharmacology, and aging-brain research.
AI & Machine LearningLongevityWellness & FitnessSan Francisco, US
Lycos PBC develops investigational psychedelic-based therapeutics to treat mental health conditions, with an initial focus on post-traumatic stress disorder.
BiotechDeep TechMental Health
Co-investorsJourneyOne VenturesLauder PartnersLeafy TunnelSolari CapitalWGD Capital, L.P.
Mindstate Design Labs is a clinical-stage drug development company that uses AI to map the biological basis of emotion and cognition, synthesizing psychedelic phenomenology and biochemical data to design pharmaceutical compounds that induce specific therapeutic emotional and cognitive states for mental health treatment.
AI & Machine LearningBiotechHealthtechMental HealthSan Francisco, US
Dillan DiNardo(Founder/CEO)inTom Ray(Founder)in
BoardRand Hindi(Director)in
Co-investorsImmeasurableMetaplanetPsyMed VenturesY CombinatorDay One VenturesInitialized Capital+3 more
Motif Neurotech develops a therapeutic brain-computer interface using minimally invasive neuromodulation to treat difficult-to-treat mental health conditions such as depression.
BiotechDeep TechDigital HealthHealthtechMedical DevicesHouston, US
Sameer Sheth(Founder)inSunil Sheth(Founder)Nick Halper(Chief Operating Officer)inSteve Goetz(Chief Technology Officer)inAnthony Arnold(Director)in
BoardJacob Robinson(Co-founder & CEO)in
Co-investorsArboretum VenturesFeatures Capital HoldingsPsyMed VenturesTMC Venture FundCapital FactoryDivergent Capital+4 more
NeuroBionics develops soft, flexible neural interface technologies for neuromodulation applications.
BiotechDeep TechHealthtechMedical DevicesSomerville, US
MJ Antonini(Founder, CEO)inNicki Driscoll(Founder, CTO)Polina Anikeeva(Founder)in
Co-investorsFuture VenturesGreyMatterVanedge CapitalVanedge Capital Limited PartnershipDolby Family VenturesLIONHEART VENTURES
Pangea Bio develops therapies targeting central nervous system and mental health disorders by activating the TrkB receptor pathway to promote neuronal survival and synaptic plasticity.
BiotechDeep TechDigital Health
Co-investorsMetaplanetNO LABEL VENTURESSeaside VenturesVox Capital
Platform accelerating drug discovery for untreatable diseases.
BiotechDedham, US
Samantha Dale Strasser(Director)Jon (Yu) Hu(Founder)inYu Hu(Executive Officer, Director)
BoardOmri Amirav-Drory(Director)in
Co-investorsbig_betsSilverton PartnersMana VenturesNFXVSC Ventures
TARA Mind offers a specialized, clinician-guided mental health benefit that employers add to their existing benefits to serve workers with treatment-resistant conditions, connecting them to a vetted U.S. network of therapists and physicians for evidence-based care.
Digital HealthHR TechMental Health
Marcus Capone(Founder & CEO)in
Co-investorsRed Cell IncubationPrime Movers Lab
Ultra Bionics develops implantable focused ultrasound technology placed inside the skull to deliver targeted, adaptive neuromodulation for treating neurological diseases, beginning with Parkinson's disease.
Deep TechHealthtechMedical DevicesMelbourne, AU
Xylo develops mechanism-based drug therapies targeting psychiatric and neurological disorders using computational and rational drug design approaches.
BiotechDeep TechDigital HealthHealthtechSydney, AU
Joshua Ismin(Co-founder, President)inDr. Sam Banister(Co-founder, Chief Scientific Officer)
Co-investorsRadar VenturesCapitalTCommon MagicSure Valley Ventures
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
ApertureBeondBiosphereForecast BioFreedomKadenceKerna LabsLykosMotifMycrodose TherapeuticsPangeaPodcastSuperpowerSynchronTippingPointWonder
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.